Bladder cancer is the fifth most common cancer in Canada and the incidence is increasing. Superficial disease is treated by surgical removal of tumors and the intravesical instillation of chemotherapy agents directly into the bladder via a catheter. However, the highly impermeable barrier presented by the superficial bladder mucosa seriously limit drug uptake and effectiveness of intravesical chemotherapy. Our work to develop very stable nanoparticulate hyperbranched polyglycerols (HPGs) modified to produce a hydrophobic core for drug loading (docetaxel!) and surface amine groups to increase drug uptake, retention in bladder and provide greater efficacy in treating superficial bladder cancer will be discussed.